Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Arcadia Biosciences in a research report on Friday, April 5th.

Arcadia Biosciences Trading Down 4.2 %

Arcadia Biosciences stock opened at $2.03 on Friday. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $7.30. The company has a market cap of $2.76 million, a PE ratio of -0.14 and a beta of 0.60. The company’s 50-day moving average is $2.41 and its two-hundred day moving average is $2.75.

Arcadia Biosciences (NASDAQ:RKDA) last released its earnings results on Thursday, March 28th. The basic materials company reported ($2.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.20. The company had revenue of $1.17 million for the quarter, compared to the consensus estimate of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. Research analysts forecast that Arcadia Biosciences will post -5.01 EPS for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.